ArticleMediators of inflammation2015
Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort.
Article in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 79 citations in OpenAlex.
- Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Predictive Value of Laboratory Assays Toward Autoimmune Diseases.Journal of clinical laboratory analysis · 2025Article
- Discovery of Blood-Based Proteins That Mark Benzo[a]pyrene Modulation of Autoimmunity.International journal of molecular sciences · 2025Article
- Adult-onset Seizures as the First Manifestation of Anti-dsDNA Negative Systemic Lupus Erythematosus.Oman medical journal · 2025Article
- Article
- Characterization of Clinicopathological Features and Autoantibody Profiles in Patients with Cutaneous Lupus Erythematous: A Single-Center Retrospective Study.American journal of clinical dermatology · 2025Article
- Double positivity for anti-dsDNA and anti-Sm antibodies represents higher disease activity in systemic lupus erythematosus.Therapeutic advances in musculoskeletal disease · 2025Article
- Structural Brain MR Imaging Alterations in Patients with Systemic Lupus Erythematosus with and without Neuropsychiatric Events.AJNR. American journal of neuroradiology · 2024Article
- Precise Targeting of Autoantigen-Specific B Cells in Lupus Nephritis with Chimeric Autoantibody Receptor T Cells.International journal of molecular sciences · 2024Article
- Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment.Molecules (Basel, Switzerland) · 2024Review
- Relationship between clinical manifestations and serological profile in patients affected by Systemic Lupus Erythematosus.Frontiers in immunology · 2024Article
- Article
- Serological and clinical associations of autoantibodies in Chinese patients with new-onset systemic lupus erythematosus.Scientific reports · 2023Article
- Benzo[a]pyrene Exposure Reduces Cell-Type Diversity and Stimulates Sex-Biased Damage Pathways in End Organs of Lupus-Prone Mice.International journal of molecular sciences · 2023Article
- A 28-Year-Old Woman Presenting with a Clinical Flare of Systematic Lupus Erythematosus and Abdominal Pain Due to Rectus Sheath Hematoma.The American journal of case reports · 2022Article
- Review
- SLE classification criteria: Science-based icons or algorithmic distractions - an intellectually demanding dilemma.Frontiers in immunology · 2022Article
- The expansion of activated naive DNA autoreactive B cells and its association with disease activity in systemic lupus erythematosus patients.Arthritis research & therapy · 2021Article
- Phenotypic and Functional Consequences of PLT Binding to Monocytes and Its Association with Clinical Features in SLE.International journal of molecular sciences · 2021Article
- Systemic lupus erythematosus multiorgan flare with quiescent serologic markers.BMJ case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe anti-dsDNA antibodies are a marker for Systemic Lupus Erythematosus (SLE) and 70-98% of patients test positive. We evaluated the demographic, clinical, laboratory, and therapeutical features of a monocentric SLE cohort according to the anti-dsDNA status.
methodsWe identified three groups: anti-dsDNA + (persistent positivity); anti-dsDNA ± (initial positivity and subsequent negativity during disease course); anti-dsDNA - (persistent negativity). Disease activity was assessed by the European Consensus Lupus Activity Measurement (ECLAM).
resultsWe evaluated 393 patients (anti-dsDNA +: 62.3%; anti-dsDNA ±: 13.3%; anti-dsDNA -: 24.4%). The renal involvement was significantly more frequent in anti-dsDNA + (30.2%), compared with anti-dsDNA ± and anti-dsDNA - (21.1% and 18.7%, resp.; P = 0.001). Serositis resulted significantly more frequent in anti-dsDNA - (82.3%) compared to anti-dsDNA + and anti-dsDNA ± (20.8% and 13.4%, resp.; P < 0.0001). The reduction of C4 serum levels was identified significantly more frequently in anti-dsDNA + and anti-dsDNA ± (40.0% and 44.2%, resp.) compared with anti-dsDNA - (21.8%, P = 0.005). We did not identify significant differences in the mean ECLAM values before and after modification of anti-dsDNA status (P = 0.7).
conclusionAnti-dsDNA status influences the clinical and immunological features of SLE patients. Nonetheless, it does not appear to affect disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.